Search results for "AGENT"

showing 10 items of 8904 documents

Antibiotic resistance among Shigella serogroups isolated in Tehran, Iran (2002-2004)

2009

Shigellosis, one of the most common bacterial diarrhoeal diseases, is endemic throughout the world. It is one of the major causes of morbidity in children with diarrhoea in Iran [1-4]. Antibiotic therapy is useful and effective for shigellosis. Treatment is critical for persons with severe disease, particularly children and immunosuppressed patients. Use of an appropriate antibiotic therapy can shorten the duration of symptoms, significantly reduce the risk of transmission, and also prevent potentially lethal complications [5-7]. However, high frequencies of resistance in

medicine.medical_specialtyShigellosisSevere diseaseIranSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeMicrobiologyMicrobiologyAntibiotic resistanceVirologyAntibiotic therapyInternal medicineDrug Resistance BacterialmedicineHumansShigellaChildDysentery BacillaryShigella Antibiotic resistance IranTransmission (medicine)Diarrhoeal diseasebusiness.industryGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesChild PreschoolParasitologyShigellabusinessThe Journal of Infection in Developing Countries
researchProduct

A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis

2021

Abstract Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Although several oral triggers can initiate MRONJ, invasive oral treatments and tooth extraction still remain the most common precipitating event. In general, tooth extraction and oral surgery should be avoided in patients at increased risk of MRONJ, while extraction of non-restorable teeth should be performed based on specific risk reduction protocols to eliminate dental/periodontal infections, still protecting from MRONJ onset. Based on th…

medicine.medical_specialtySide effectOsteoporosisSpecialties of internal medicine030209 endocrinology & metabolismMRONJOral surgery tooth extraction03 medical and health sciences0302 clinical medicineOral surgeryMedication-related osteonecrosis of the jawmedicineDenosumab osteoporosis; Medication-related osteonecrosis of the jaw; MRONJ; Oral surgery tooth extraction; Denosumab; Diphosphonates; Humans; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; OsteoporosisHumansIntensive care medicineGeneral Dentistrytooth extractionBisphosphonate-associated osteonecrosis of the jawDiphosphonatesBone Density Conservation Agentsbusiness.industryHypothesismedicine.diseaseosteoporosisDenosumab osteoporosisBone Density Conservation Agentsstomatognathic diseasesDenosumabOtorhinolaryngologyRC581-951030220 oncology & carcinogenesisDental surgeryOral and maxillofacial surgeryBisphosphonate-Associated Osteonecrosis of the JawNeurology (clinical)DenosumabbusinessOsteonecrosis of the jawmedicine.drugHead & Face Medicine
researchProduct

The addition of simvastatin administration to cold storage solution of explanted whole liver grafts for facing ischemia/reperfusion injury in an area…

2018

Abstract Background Liver transplantation is the best treatment for end-stage liver disease. The interruption of the blood supply to the donor liver during cold storage damages the liver, affecting how well the liver will function after transplant. The drug Simvastatin may help to protect donor livers against this damage and improve outcomes for transplant recipients. The aim of this study is to evaluate the benefits of treating the donor liver with Simvastatin compared with the standard transplant procedure. Patient and methods We propose a prospective, double-blinded, randomized phase 2 study of 2 parallel groups of eligible adult patients. We will compare 3-month, 6-month, and 12-month g…

medicine.medical_specialtySimvastatinmedicine.medical_treatmentlcsh:SurgeryCold storageIschemia/reperfusion injury030230 surgeryLiver transplantationDonor after brain deathPlaceboProtective Agents03 medical and health sciencesLiver diseaseStudy Protocol0302 clinical medicineDouble-Blind MethodDonor after brain death; Ischemia/reperfusion injury; Liver transplantation; SimvastatinMedicineHumansProspective StudiesLiver transplantationbusiness.industrylcsh:RD1-811General Medicinemedicine.diseaseSurgeryTransplantationFatty LiverRegimenLiverSimvastatinReperfusion Injury030211 gastroenterology & hepatologySurgerybusinessReperfusion injurymedicine.drugBMC surgery
researchProduct

S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018

2019

Merkel cell carcinoma (MCC, ICD-O M8247 / 3) is a rare malignant primary skin tumor with epithelial and neuroendocrine differentiation. The neoplastic cells share many morphological, immunohistochemical and ultrastructural characteristics with Merkel cells of the skin. The diagnosis of MCC is rarely made on clinical grounds. Histological and immunohistochemical studies are usually required to confirm the clinical suspicion. Given the frequent occurrence of occult lymph node metastasis, sentinel lymph node biopsy should be performed once distant metastasis has been ruled out by cross-sectional imaging. Primary tumors without evidence of organ metastases are treated with complete surgical exc…

medicine.medical_specialtySkin Neoplasmsmedicine.medical_treatmentSentinel lymph nodeMedizinAntineoplastic AgentsDermatologyNeuroendocrine differentiation030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineBiopsyCarcinomaHumansMedicineNeoadjuvant therapyAgedNeoplasm Stagingmedicine.diagnostic_testbusiness.industryMerkel cell carcinomaPrognosismedicine.diseaseNeoadjuvant TherapyCarcinoma Merkel CellRadiation therapymedicine.anatomical_structureLymphatic MetastasisImmunotherapyRadiologyNeoplasm Recurrence LocalCognition DisordersbusinessMerkel cell
researchProduct

Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?

2005

The term "lipid triad" or "atherogenic lipoprotein phenotype" has been introduced to describe a common form of dyslipidemia, characterized by three lipid abnormalities: increased plasma triglyceride levels, decreased HDL-cholesterol concentrations and the presence of small, dense LDL particles. It has been suggested that the clinical importance of the atherogenic lipoprotein phenotype probably exceeds that of LDL-cholesterol, because many more patients with coronary artery disease are found to have this trait than hypercholesterolaemia. There is a body of evidence that therapies effective against plasma HDL-cholesterol and triglycerides are associated with a strong reduction of cardiovascul…

medicine.medical_specialtySmall dense ldlBiologyCoronary artery diseaseCardiovascular preventionInternal medicineInternal MedicinemedicineHumansNational Cholesterol Education ProgramDyslipidemiasHypolipidemic AgentsLDL HDL triglycerides preventionBiochemistry (medical)LDL Particle SizeTriad (anatomy)Atherogenic lipoprotein phenotypemedicine.diseaseAtherosclerosisLipoproteins LDLEndocrinologymedicine.anatomical_structureCardiovascular Diseaseslipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineDyslipidemiaJournal of atherosclerosis and thrombosis
researchProduct

The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates

2007

Beyond total low-density-lipoproteins (LDL) levels, increasing evidence suggests that the 'quality' of LDL exerts a great influence on the cardiovascular risk. Several studies have also shown that the therapeutic modulation of LDL size is of benefit in reducing the risk of cardiovascular events. Hypolipidaemic treatment is able to alter LDL subclass distribution but strong variations have been noticed among different agents. Fibrates have a major impact on triglyceride metabolism and in modulating LDL size and subclasses, but variations exist among the different molecules.A literature search (by Medline and Scopus) was performed using the following headings: 'small dense LDL', 'LDL size', '…

medicine.medical_specialtySmall dense ldlClofibric AcidFenofibrateInternal medicinemedicineLow densityHumansGemfibrozilClinical significanceParticle SizeDyslipidemiasHypolipidemic AgentsBezafibrateFenofibratebusiness.industryBezafibrateDense low density lipoproteinFenofibrate Gemfibrozil Subfractions TherapyLdl subfractionsFibric AcidsGeneral MedicineLipoproteins LDLTreatment OutcomeEndocrinologylipids (amino acids peptides and proteins)CiprofibrateBezafibrateGemfibrozilbusinessmedicine.drug
researchProduct

Tratamiento integral de la dislipidemia diabética: beneficios y nuevas alternativas terapéuticas

2010

Diabetic dyslipidemia, characterized by the lipid triad (elevated plasma triglycerides, low HDL cholesterol and predominance of small, dense LDL particles), is a significant contributor to the elevated cardiovascular risk of type 2 diabetic patients. Statin monotherapy has shown, in different prospective trials, significant reductions in cardiovascular events and mortality. However, the residual risk in these subjects remains elevated, probably due to the incomplete control of diabetic dyslipidemia. In this review we discuss the global therapeutic approach, underlying the need of combining statins with agents that more effective in reducing triglycerides and elevating HDL cholesterol, even …

medicine.medical_specialtySmall dense ldlStatinmedicine.diagnostic_testCholesterolbusiness.industrymedicine.drug_classnutritional and metabolic diseasesGeneral MedicineResidual riskClinical trialchemistry.chemical_compoundTherapeutic approachEndocrinologychemistryInternal medicineHypolipidemic AgentsmedicineCardiologylipids (amino acids peptides and proteins)Lipid profilebusinessMedicina Clínica
researchProduct

Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence

2018

BACKGROUND Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults. In some European Union countries, sodium oxybate is applied for the treatment of opioid and alcohol withdrawal. OBJECTIVE The aim of the present review was to describe the state of art of the pre-clinical research and the clinical evidence related to GHB used alone or in combination with other treatments in alcohol withdrawal syndrome and alcohol abstinence maintenance. METHOD Internationally published pre-clinical findings and clinical studi…

medicine.medical_specialtySodium Oxybatemedia_common.quotation_subjectClinical Biochemistry01 natural sciencesNaltrexone03 medical and health sciences0302 clinical medicinemedicineHumansmedia_common.cataloged_instance030216 legal & forensic medicineEuropean unionPsychiatrymedia_commonPharmacologyAlcohol Abstinencebusiness.industry010401 analytical chemistryGamma hydroxybutyrategamma-Hydroxybutyric acidAbstinencemedicine.diseaseSubstance Withdrawal Syndrome0104 chemical sciencesAlcohol withdrawal syndromeSodium OxybatebusinessAlcohol-Related DisordersCentral Nervous System AgentsAlcohol Abstinencemedicine.drugCurrent Drug Metabolism
researchProduct

Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion.

1999

Activation of Na+/H+ exchange and subsequent calcium overload in cardiac myocytes appear to play an important role in myocardial tissue injury following ischemia and reperfusion. Results of several in vitro studies in isolated myocytes and heart preparations and in vivo studies in pigs and rats have suggested that inhibition of Na+/H+ exchange is an effective means to prevent lethal reperfusion injury, arrhythmia, and improve myocardial contractile dysfunction. In patients with acute myocardial infarction (MI), any preventive agent is administered immediately before or shortly after reperfusion, rather than before the occurrence of coronary occlusion. The direct interventional approach to t…

medicine.medical_specialtySodium-Hydrogen Exchangersmedicine.medical_treatmentPremedicationIschemiaMyocardial InfarctionMyocardial Reperfusion InjuryPilot ProjectsGuanidineschemistry.chemical_compoundInternal medicineAngioplastyLactate dehydrogenasemedicineAnimalsHumansMyocardial infarctionSulfonesAngioplasty Balloon CoronaryInfusions IntravenousCariporidebiologybusiness.industrymedicine.diseaseRatschemistryCoronary occlusionAnesthesiaCardiologybiology.proteinCreatine kinaseCardiology and Cardiovascular MedicinebusinessReperfusion injuryAnti-Arrhythmia AgentsThe American journal of cardiology
researchProduct

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

2015

Objective:Across Italy up to 7.3% of the population is infected with hepatitis C virus (HCV), with long-term complications resulting in high medical costs and significant morbidity and mortality. Current treatment options have limitations due to side effects, interferon intolerability and ineligibility, long treatment durations and low sustained virological response (SVR) rates, especially for the most severe patients). Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir, administered with ribavirin (RBV) and with or without pegylated interferon (PEG-INF), resulted in >90% SVR across treatment-naïve (TN) genotype (GT) 1-6 patients. It is also t…

medicine.medical_specialtySofosbuvirGenotypeCost effectivenessHepatitis C virusCost-Benefit AnalysisAlpha interferonmedicine.disease_causeGastroenterologyPolyethylene GlycolAntiviral AgentsSeverity of Illness IndexTelaprevirTelaprevirPolyethylene Glycolschemistry.chemical_compoundPegylated interferonBoceprevirInternal medicineQuality-Adjusted Life YearRibavirinmedicineCost-effectiveness analysiHumansCost-Benefit AnalysiAntiviral AgentBoceprevirbusiness.industryHealth PolicyRibavirinInterferon-alphaMarkov ChainHepatitis C ChronicPatient Acceptance of Health CareVirologyChronic hepatitis C infectionMarkov ChainschemistryItalyDrug Therapy CombinationQuality-Adjusted Life YearsSofosbuvirbusinessmedicine.drugHumanJournal of medical economics
researchProduct